XML 70 R62.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details) - EUR (€) € in Thousands | 6 Months Ended
--- | ---
Jun. 30, 2024 | Jun. 30, 2023
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Revenue from collaboration and licensing agreements | € 8,293 | € 35,344
Proceeds from collaboration and licensing agreements |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Revenue from collaboration and licensing agreements | 7,396 | 34,728
Monalizumab agreement (AstraZeneca) |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Revenue from collaboration and licensing agreements | 2,994 | 9,503
Agreement with Sanofi, 2016 |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Revenue from collaboration and licensing agreements | 4,000 | 2,000
Agreement with Sanofi, 2022 - ANKET IPH62 |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Revenue from collaboration and licensing agreements | 199 | 18,672
Agreement With Sanofi 2022 - ANKET IPH67 |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Revenue from collaboration and licensing agreements | 203 | 0
Takeda agreement |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Revenue from collaboration and licensing agreements | 0 | 4,553
Invoicing of R&D costs (IPH5201 agreement) |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Revenue from collaboration and licensing agreements | € 897 | € 616

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_CollaborationAndLicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofi2022ANKETIPH62Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofi2022ANKETIPH67Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_AgreementWithTakedaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=inpha_IPH5201AndAdvoralimabAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |